Skip to main content
. Author manuscript; available in PMC: 2016 Jun 24.
Published in final edited form as: Lancet. 2015 Oct 1;386(10012):2489–2498. doi: 10.1016/S0140-6736(15)00347-5

Table 3.

Univariable analysis (chi-squared test of independence) for the proportion of patients achieving a response at 48 weeks post-randomisation (evaluable patient population) for the key secondary endpoints

Outcome at 48 weeks Tight control n (%) Standard care n (%) Difference in proportions (%) & 95% CIs (TC-StdC) p-value
ACR20 55/89 (61·8) 37/84 (44·0) 17·8 (3·1, 32·4) 0·0194
ACR50 44/86 (51·2) 21/84 (25·0) 26·2 (12·1, 40·2) 0·0004
ACR70 33/87 (37·9) 15/86 (17·4) 20·5 (7·5, 33·5) 0·0026
PASI75 44/75 (58·7) 27/81 (33·3) 25·3 (10·2, 40·5) 0·0015

ACR, American College of Rheumatology; PASI, Psoriasis Area Severity Index.